Evaluate the Safety and Efficacy of Short Versus Long Infusion Schedules of Evomela As Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma.Interpret Bayesian Modeling Results Assessing the Relationship between Melphalan Exposure (AUC) and Depth of Response or Progression-Free Survival.Identify Potential Pharmacokinetic (AUC) Targets That May Guide Individualized Evomela Dosing Strategies, Particularly for Patients with High-Risk Cytogenetics

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Qaiser Bashir, Peter F. Thall, Xun Xu, Jitesh D. Kawedia, Cristina Knape, Ruby Delgado, Uday Popat, Chitra M. Hosing, Yosra M. Aljawai, George L. Chen, Warren Benjamin Fingrut, Jin S. Im
+17 more Partow Kebriaei, David Marin, Yago L. Nieto, Sairah Ahmed, Amanda Leigh Olson, Betül Oran, Jeremy Ramdial, Neeraj Y. Saini, Portia Smallbone, Samer A. Srour, Oren Pasvolsky, Sheeba K. Thomas, Christine Ye, Krina K. Patel, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash
DOI: 10.1016/j.jtct.2025.12.601
Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Multiple Sclerosis Research Studies

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S419–S420
Publication date
1 February 2026
Language
EN